Rare disease day takes place on February 28th of each year. The entire week provides a unique opportunity to advocate and raise awareness of key policy issues that affect amyloidosis patients. (more…)
Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial, (more…)
Finding the best amyloidosis care is not easy, so in 2017 ARC created My Amyloidosis Pathfinder (MAP) to help you discover, learn about, and contact treatment centers and clinical trials that are right for you. Now MAP can do even more. (more…)
The 2018 annual meeting of the American Society of Hematology (ASH) featured the latest scientific updates, including advances in treatment and new insights in amyloidosis. (more…)
NICE issue initial negative decisions on inotersen and patisiran
The UK’s National Institute for Health and Care Excellence (NICE) has published Evaluation Consultation Documents on its assessments of inotersen and patisiran. (more…)
Join our email list to stay up to date on the latest Amyloidosis news.
In this ARC TALKS webinar, Dr. Nativi-Nicolau and Dr. Elizabeth Mauricio discussed the decision pathway in management of ATTR amyloidosis from the cardiac and neurological standpoint.
Watch the recording to learn more about interdisciplinary approaches to ATTR amyloidosis care.
Original Presentation Date:
July 31, 2023
Key Webinar Highlights:
0:00 — Introduction
3:24 — Management of TTR amyloidosis (cardiac approaches)
8:37 — Constellation of symptoms checklist
16:43 — Disease modifying options in ATTR amyloidosis
22:22 — When should cardiology consult neurology?
24:42 — Management of TTR amyloidosis (neurologic manifestations)
28:11 — Investigating for neurologic manifestations
33:31 — Management of neuropathy
38:28 — Management of autonomic dysfunction
42:03 — Management of carpal tunnel syndrome
45:55 — Do hereditary and wild-type amyloidosis symptoms sort distinctly into neurologic and cardiac manifestations?
47:50 — How to tell the difference between diabetic and amyloid-related neuropathy?
48:36 — Is there a good approach to combination therapies?
51:06 — How to participate in clinical trials?
54:09 — Are there hereditary ATTR genes that haven’t been discovered?
56:14 — What’s the distinction between peripheral neuropathy and polyneuropathy?
58:07 — Are there any options for amyloid degraders?
1:00:29 — How can we raise awareness for earlier diagnosis?